Literature DB >> 22640448

HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era.

E Palacios1, M Franke, M Muñoz, R Hurtado, R Dallman, K Chalco, D Guerra, L Mestanza, K Llaro, C Bonilla, J Sebastian, J Bayona, M Lygizos, M Lyzigos, H Anger, S Shin.   

Abstract

SETTING: Multidrug-resistant tuberculosis (MDR-TB) and the human immunodeficiency virus (HIV) pose two of the greatest threats to global tuberculosis (TB) control. Given expanding global access to antiretroviral therapy (ART) and second-line TB drugs, more data are needed on experiences treating MDR-TB and HIV co-infection in resource-poor settings.
OBJECTIVE: To describe the clinical characteristics, management, outcomes, and factors associated with survival among HIV-positive individuals receiving treatment for MDR-TB.
DESIGN: This was a retrospective case series of 52 HIV-positive individuals receiving treatment for MDR-TB in Lima, Peru. We used Cox proportional hazards regression models to identify risk factors for mortality.
RESULTS: A total of 31 (57%) of the cohort died on treatment, with the majority of deaths due to MDR-TB. Low baseline weight predicted a three-fold increased rate of death (aHR 3.1, 95%CI 1.5-6.7), while individuals receiving highly active ART experienced a significantly lower rate of death compared to those who were not (aHR 0.4, 95%CI 0.2-0.9).
CONCLUSION: Early ART is likely a key component of effective MDR-TB management in co-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22640448     DOI: 10.5588/ijtld.11.0473

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  20 in total

1.  Management and treatment outcomes of patients enrolled in MDR-TB treatment in Viet Nam.

Authors:  N T M Phuong; N V Nhung; N B Hoa; H T Thuy; K C Takarinda; K Tayler-Smith; A D Harries
Journal:  Public Health Action       Date:  2016-02-11

2.  Predictors of unfavourable treatment outcome in patients with multidrug-resistant tuberculosis in India.

Authors:  D Nair; B Velayutham; T Kannan; J P Tripathy; A D Harries; M Natrajan; S Swaminathan
Journal:  Public Health Action       Date:  2017-03-21

3.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

4.  Treatment outcomes for patients with multidrug-resistant tuberculosis in post-earthquake Port-au-Prince, Haiti.

Authors:  Macarthur Charles; Stalz Charles Vilbrun; Serena P Koenig; Lauren M Hashiguchi; Marie Marcelle Mabou; Oksana Ocheretina; Jean W Pape
Journal:  Am J Trop Med Hyg       Date:  2014-07-28       Impact factor: 2.345

Review 5.  HIV and tuberculosis--science and implementation to turn the tide and reduce deaths.

Authors:  Anthony D Harries; Stephen D Lawn; Haileyesus Getahun; Rony Zachariah; Diane V Havlir
Journal:  J Int AIDS Soc       Date:  2012       Impact factor: 5.396

6.  Healthcare worker perceived barriers to early initiation of antiretroviral and tuberculosis therapy among Tanzanian inpatients.

Authors:  Bahati M K Wajanga; Robert N Peck; Samuel Kalluvya; Daniel W Fitzgerald; Luke R Smart; Jennifer A Downs
Journal:  PLoS One       Date:  2014-02-14       Impact factor: 3.240

7.  Outcomes of multidrug-resistant tuberculosis treatment with early initiation of antiretroviral therapy for HIV co-infected patients in Lesotho.

Authors:  Hind Satti; Megan M McLaughlin; Bethany Hedt-Gauthier; Sidney S Atwood; David B Omotayo; Likhapha Ntlamelle; Kwonjune J Seung
Journal:  PLoS One       Date:  2012-10-24       Impact factor: 3.240

8.  Aggressive regimens for multidrug-resistant tuberculosis decrease all-cause mortality.

Authors:  Carole D Mitnick; Molly F Franke; Michael L Rich; Felix A Alcantara Viru; Sasha C Appleton; Sidney S Atwood; Jaime N Bayona; Cesar A Bonilla; Katiuska Chalco; Hamish S F Fraser; Jennifer J Furin; Dalia Guerra; Rocio M Hurtado; Keith Joseph; Karim Llaro; Lorena Mestanza; Joia S Mukherjee; Maribel Muñoz; Eda Palacios; Epifanio Sanchez; Kwonjune J Seung; Sonya S Shin; Alexander Sloutsky; Arielle W Tolman; Mercedes C Becerra
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

9.  Adverse events among HIV/MDR-TB co-infected patients receiving antiretroviral and second line anti-TB treatment in Mumbai, India.

Authors:  Petros Isaakidis; Bhanumati Varghese; Homa Mansoor; Helen S Cox; Joanna Ladomirska; Peter Saranchuk; Esdras Da Silva; Samsuddin Khan; Roma Paryani; Zarir Udwadia; Giovanni Battista Migliori; Giovanni Sotgiu; Tony Reid
Journal:  PLoS One       Date:  2012-07-11       Impact factor: 3.240

10.  Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia--an observational cohort study.

Authors:  Daniel Meressa; Rocío M Hurtado; Jason R Andrews; Ermias Diro; Kassim Abato; Tewodros Daniel; Paritosh Prasad; Rebekah Prasad; Bekele Fekade; Yared Tedla; Hanan Yusuf; Melaku Tadesse; Dawit Tefera; Abraham Ashenafi; Girma Desta; Getachew Aderaye; Kristian Olson; Sok Thim; Anne E Goldfeld
Journal:  Thorax       Date:  2015-10-27       Impact factor: 9.139

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.